Cold Agglutinin Disease Treatment Market Size
The global Cold Agglutinin Disease (CAD) Treatment Market was valued at approximately USD 119.62 million in 2025 and is projected to reach USD 996.78 million by 2035, expanding at a CAGR of 24.8% during the forecast period 2026–2035. The market is entering a high-growth phase as the treatment landscape shifts from supportive care and off-label immunosuppression toward targeted complement therapies and disease-specific biologics. The approval and commercial adoption of sutimlimab (Enjaymo) have established a targeted treatment category for CAD, while growing diagnosis of rare autoimmune hemolytic anemia is expanding the addressable patient population.
Investment activity is increasingly focused on next-generation, convenient, and potentially durable CAD therapies. A major commercial signal came when Recordati acquired global rights to Enjaymo from Sanofi for USD 825 million, with up to USD 250 million in additional commercial milestone payments, demonstrating the strategic value of targeted CAD treatments. Meanwhile, Annexon is advancing ANX1502, an oral C1s inhibitor, through a proof-of-concept study in CAD, with clinical updates anticipated in 2026. Biohaven is also developing BHV-1490, an IgM-degrading therapy designed to address IgM-mediated diseases including CAD. The competitive opportunity is therefore shifting toward oral administration, longer-lasting disease control, reduced infusion burden, and precision targeting, making CAD one of the more closely watched rare-disease treatment markets.
The global cold agglutinin disease treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A uncommon kind of autoimmune hemolytic anemia is known as cold agglutinin disease, which is brought on by autoantibodies that react to cold.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced treatments and boost the global cold agglutinin disease treatment market. The respective innovative treatments includes the use of monoclonal antibodies for better treatment.
Cold Agglutinin Disease Treatment Market Scope
| Metric | Details |
| Market Size in 2025 | USD 119.62 million |
| Market Size in 2035 | USD 996.78 million |
| CAGR | 24.80% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Type, Drug Type, Route of Administration, Distribution Channel and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, Middle East & Africa |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
To Know More Insights - Download Sample
Cold Agglutinin Disease Treatment Market Dynamics
Growing development of novel therapies or drugs
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for cold agglutinin disease treatment owing to its positive outcomes in clinical trials leading to drug approval will be a crucial factor driving the growth of the market.
On July 7, 2023, with less red blood cell damage in a cellular model of CAD, Sanofi's investigational medication SAR445088 successfully inhibits the traditional complement pathway, a component of the immune system linked to cold agglutinin disease (CAD) in a study. Because of its more focused activity, SAR445088 might replace Sanofi's Enjaymo (sutimlimab-jome). Adults with CAD are being investigated with the next-generation treatment in a Phase 1 clinical trial in Europe (NCT04802057). Rising awareness among people and increasing robust pipeline with drugs in phase 3 will be a major factor driving the growth of the cold agglutinin syndrome drugs market.
Restraints
Side effects associated with the drugs
Patients having symptomatic anemia or other annoying symptoms should be addressed, while medication is not always necessary. Due to their negative effects, corticosteroids are not recommended to treat CAD. Heart or heart rhythm issues, such as arrhythmia, heart attacks, and cardiogenic shock, could be brought on by this medication. When mAbs are administered, there is a chance of immunological reactions like serum sickness, acute anaphylaxis, and the production of antibodies.
Cold Agglutinin Disease Treatment Market Segmentation Analysis
The global cold agglutinin disease treatment market is segmented based on type, drug type, route of administration, distribution channel and region.
Biologics segment holds approximately 37% of market share
The biologics segment from drug type is the largest share holder among all the drug types owing to its high effectiveness and rising researches and product developments. Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines.
Rituximab, a monoclonal antibody, is the first- and second-line treatment for cold agglutinin illness as well as the preferred therapy for steroid-refractory warm autoimmune hemolytic anemia (wAIHA).
Cold Agglutinin Disease Treatment Market Geographical Share
North America accounted for around 33% of market share in 2025
Due to the rising need for cold agglutinin disease treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cold agglutinin disease treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of drugs for treatment, and increase in pharmaceutical or biotech business establishment across the region are also contributing to the growth of cold agglutinin disease treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments such as monoclonal antibodies. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global cold agglutinin disease treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cold agglutinin disease treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cold agglutinin disease treatment drugs demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cold agglutinin disease treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various types of drugs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cold agglutinin disease treatment. Now several research studies have been initiated and companies have again started trial for their respective pipelines. Overall, the impact of the pandemic on the global cold agglutinin disease treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for monoclonal antibodies and other programs to control such kind of disorders.
Key Developments
June 2026: Sanofi’s Enjaymo (sutimlimab-jome) continued to anchor the CAD treatment landscape as the established complement-targeted therapy for hemolysis in adults with cold agglutinin disease. The treatment selectively inhibits the classical complement pathway and remains an important option for reducing hemolysis and transfusion requirements.
May 2026: Novartis continued development of iptacopan, an oral factor B inhibitor, in complement-mediated diseases, supporting broader industry efforts to develop oral therapies targeting the alternative complement pathway. Complement-pathway modulation remains an important area of innovation for CAD, where existing therapies primarily address hemolysis rather than the underlying B-cell clone.
April 2026: Recordati continued supporting the multinational Cold Agglutinin Disease Real World Evidence Registry, which is collecting longitudinal clinical data from patients with CAD and CAS, including patients treated with sutimlimab. The registry is strengthening real-world evidence on treatment patterns, outcomes, and long-term disease management across multiple countries.
March 2026: Sobi/Sanofi continued expanding the clinical evidence base for sutimlimab, with recent analyses reinforcing its ability to rapidly control complement-mediated hemolysis and improve hemoglobin levels in CAD. The development is supporting continued adoption of targeted complement inhibition across North America and Europe.
February 2026: Clinical-stage developers continued exploring next-generation approaches for CAD, including pegcetacoplan, a complement C3 inhibitor being evaluated for its potential to increase hemoglobin levels and reduce transfusion requirements. The pipeline reflects growing interest in targeting complement at different points to improve disease control and expand treatment options.
Cold Agglutinin Disease Treatment Market Companies
The major global players in the market include Sanofi, NovelMed Inc., Novartis AG, Swedish Orphan Biovitrum AB, Apellis Pharmaceuticals, Inc., Alpine Immune Sciences, Genentech USA, Inc., Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. and Viatris Inc. among others.
Why Purchase the Report?
- To visualize the global cold agglutinin disease treatment market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of cold agglutinin disease treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global cold agglutinin disease treatment market report would provide approximately 69 tables, 68 figures and 186 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
